AMAG rises as Feraheme prospects broaden
This article was originally published in Scrip
AMAG Pharmaceuticals' attempts to broaden the label of its iron deficiency product Feraheme have made an encouraging start, prompting a short-lived 10% leap in its share price in after-hours trading.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.